Exelixis Inc. (EXEL)

29.51
NASDAQ : Health Technology
Prev Close 29.10
Day Low/High 28.44 / 29.51
52 Wk Low/High 18.03 / 32.50
Avg Volume 2.49M
Exchange NASDAQ
Shares Outstanding 295.85M
Market Cap 8.58B
EPS -0.30
P/E Ratio 54.91
Div & Yield N.A. (N.A)

Latest News

Exelixis To Release Fourth Quarter And Full Year 2017 Financial Results On Monday, February 26, 2018

Exelixis To Release Fourth Quarter And Full Year 2017 Financial Results On Monday, February 26, 2018

Exelixis, Inc. (NASDAQ: EXEL) announced today that its fourth quarter and full year 2017 financial results will be released on Monday, February 26, 2018 after the markets close.

Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Genitourinary (GU) Tumors

Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Genitourinary (GU) Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced updated data from expansion cohorts in a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory...

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 14

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 14

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Jim Cramer highlights Anthem, A.O. Smith, Tableau Software, Electro Scientific Industries, CRISPR Therapeutics.

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Jim Cramer says this is the scary process that gets us back to where we can maintain a real, not parabolic, advance.

Exelixis Larger Than S&P 500 Component Federal Realty Investment Trust

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Exelixis Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Federal Realty Investment Trust , according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Exelixis Announces Presentation Of Updated Phase 1b Results For The Combination Of Cobimetinib And Atezolizumab In Metastatic Colorectal Cancer At The 2018 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Exelixis Announces Presentation Of Updated Phase 1b Results For The Combination Of Cobimetinib And Atezolizumab In Metastatic Colorectal Cancer At The 2018 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of updated results from the Genentech-sponsored phase 1b clinical trial of cobimetinib (COTELLIC ®), an Exelixis-discovered MEK inhibitor, in...

CELESTIAL Trial Design Fact Sheet

CELESTIAL Trial Design Fact Sheet

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced detailed results of the pivotal phase 3 CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma (HCC),...

Exelixis To Co-Host Financial Community Briefing To Discuss Data Presented At The 2018 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Exelixis To Co-Host Financial Community Briefing To Discuss Data Presented At The 2018 American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

Exelixis, Inc. (NASDAQ: EXEL) today announced that the company, along with its partner Ipsen, will host a live briefing event for the financial community to discuss data presented at the 2018 American Society of Clinical...

Exelixis And StemSynergy Enter Into Exclusive Licensing Agreement For The Discovery And Development Of Novel Anticancer Therapies

Exelixis And StemSynergy Enter Into Exclusive Licensing Agreement For The Discovery And Development Of Novel Anticancer Therapies

Exelixis, Inc. (NASDAQ: EXEL) today announced that it has entered into an exclusive collaboration and license agreement with StemSynergy Therapeutics, Inc.

Exelixis Announces Amendment To Clinical Research Protocol For Phase 1b Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Locally Advanced Or Metastatic Solid Tumors

Exelixis Announces Amendment To Clinical Research Protocol For Phase 1b Trial Of Cabozantinib In Combination With Atezolizumab In Patients With Locally Advanced Or Metastatic Solid Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced an amendment to the protocol for the phase 1b trial of cabozantinib in combination with atezolizumab (TECENTRIQ ®) in patients with locally advanced or metastatic...

CABOMETYX® Tablets 60 Mg, 40 Mg, 20 Mg (Photo: Business Wire)

CABOMETYX® Tablets 60 Mg, 40 Mg, 20 Mg (Photo: Business Wire)

Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.

Exelixis Announces Webcasts Of Upcoming November Investor Conference Presentations

Exelixis Announces Webcasts Of Upcoming November Investor Conference Presentations

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces Phase 3 CELESTIAL Trial Results Of Cabozantinib In Previously Treated Advanced Hepatocellular Carcinoma To Be Presented At 2018 Gastrointestinal Cancers Symposium

Exelixis Announces Phase 3 CELESTIAL Trial Results Of Cabozantinib In Previously Treated Advanced Hepatocellular Carcinoma To Be Presented At 2018 Gastrointestinal Cancers Symposium

Exelixis, Inc. (NASDAQ:EXEL) today announced that the phase 3 CELESTIAL trial results have been accepted as a late-breaking presentation at the 2018 ASCO-GI Symposium, which is being held January 18-20, 2018 in San...

Exelixis To Present At The Stifel 2017 Healthcare Conference On November 14th

Exelixis To Present At The Stifel 2017 Healthcare Conference On November 14th

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.

Exelixis Announces Third Quarter 2017 Financial Results And Provides Corporate Update

Exelixis Announces Third Quarter 2017 Financial Results And Provides Corporate Update

Exelixis, Inc. (NASDAQ: EXEL) today reported financial results for the third quarter of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development...

Exelixis To Present At The Credit Suisse 26th Annual Healthcare Conference On November 7th

Exelixis To Present At The Credit Suisse 26th Annual Healthcare Conference On November 7th

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CHH, EXEL, ITGR, SAH Downgrades: SVU Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Exelixis To Release Third Quarter 2017 Financial Results On Wednesday, November 1, 2017

Exelixis To Release Third Quarter 2017 Financial Results On Wednesday, November 1, 2017

Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2017 financial results will be released on Wednesday, November 1, 2017 after the markets close.

New Records for Dow, S&P 500 and Nasdaq as Apple's Gains Offset Healthcare Slide

New Records for Dow, S&P 500 and Nasdaq as Apple's Gains Offset Healthcare Slide

Apple gains offset weakness in the healthcare sector. Small increases for benchmark indexes were enough to lead them to new closing records.

Dow, Nasdaq on Track for Records as Energy and Apple Rise

Dow, Nasdaq on Track for Records as Energy and Apple Rise

Stocks are higher but retreat from intraday records on Monday.

Stocks Rise but Come Off Highs as Crude Gains Ease

Stocks Rise but Come Off Highs as Crude Gains Ease

Stocks are higher but retreat from intraday records on Monday.

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers

The South San Francisco, Calif.-based company said Oct. 16 its Phase 3 study of cabozantinib achieved its primary endpoint of overall survival in patients that have advanced hepatocellular carcinoma.

Stock Futures Tiptoe Higher as Crude Oil Tops $52

Stock Futures Tiptoe Higher as Crude Oil Tops $52

Stock futures tiptoe higher on Monday, Oct. 16, as crude oil tops $52 a barrel amid rising tensions in the Middle East.

Ipsen Announces That Phase 3 CELESTIAL Trial Of Cabozantinib Meets Primary Endpoint Of Overall Survival In Patients With Advanced Hepatocellular Carcinoma

Ipsen Announces That Phase 3 CELESTIAL Trial Of Cabozantinib Meets Primary Endpoint Of Overall Survival In Patients With Advanced Hepatocellular Carcinoma

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and its partner Exelixis (NASDAQ: EXEL) today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival (OS), with cabozantinib...

CELESTIAL Trial Fact Sheet (Graphic: Business Wire)

CELESTIAL Trial Fact Sheet (Graphic: Business Wire)

Exelixis, Inc. (NASDAQ:EXEL) today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival (OS), with cabozantinib providing a statistically significant and clinically...

Exelixis To Receive Milestone Payment From Bristol-Myers Squibb For Submission Of Clinical Trial Authorization For ROR¿t Inverse Agonist Program

Exelixis To Receive Milestone Payment From Bristol-Myers Squibb For Submission Of Clinical Trial Authorization For ROR¿t Inverse Agonist Program

Exelixis, Inc. (NASDAQ:EXEL) today announced that it has earned a $10 million milestone payment from Bristol-Myers Squibb under the terms of the two companies' worldwide collaboration for compounds targeting retinoic...

TheStreet Quant Rating: B (Buy)